Font Size:big middle small
After one year R&D, SyncoZymes become the first company in China that can make intermediate of Ibrutinib, (S)-1-Boc-3-hydroxypiperidine (CAS: 143900-44-1) on commercial production by enzymatic synthesis route.
TypeInfo: Company news
Keywords for the information: